RAP-219

Phase 3Small molecule

RRapport Therapeutics Inc.

RAP-219 is one of 119 small molecule programs targeting Bipolar I Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bipolar I DisorderActive, not recruiting

SeizureActive, not recruiting

EpilepsyActive, not recruiting

Bipolar 1 DisorderRecruiting

Focal SeizureRecruiting

Bipolar I DisorderPhase 2

Active, not recruiting

SeizurePhase 2

Active, not recruiting

EpilepsyPhase 2

Active, not recruiting

Bipolar 1 DisorderPhase 2

Recruiting

Focal SeizurePhase 3

Recruiting

Competition

Competitive Landscape

221 competitors in Epilepsy

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Phase 3

9 2

Dayvigo

Eisai

Phase 3

1 3

Depacon

AbbVie

Phase 3

1 4

Zonegran

AAzurity Pharmaceuticals

Phase 3

5 5

Fintepla

IImmedica Pharma AB

Phase 3

4 6

Actemra

GWP42003-P

1 8

Lamictal

GSK

Phase 3

2 9

Akineton

AbbVie

Phase 3

1 10

RAP-219

RRapport Therapeutics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Bipolar 1 Disorder

NCT07046494

Q1 2028

Phase 2Recruiting

Seizure

NCT07219407

Q3 2029

Phase 3Recruiting

Focal Seizure

NCT07594119

Clinical

Trials by Indication[1]

Seizure1 trial

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

Recruiting·RRapport Therapeutics Inc.·Phase 2·NCT07219407·30 enrolled

Epilepsy1 trial

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

Completed·RRapport Therapeutics Inc.·Phase 2·NCT06377930·30 enrolled

Focal Seizure1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Recruiting·RRapport Therapeutics Inc.·Phase 3·NCT07594119·312 enrolled

Bipolar 1 Disorder1 trial

A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

Recruiting·RRapport Therapeutics Inc.·Phase 2·NCT07046494·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for RAP-219. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RAP-219 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RAP-219. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rapport Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRapport Therapeutics Inc.

RAP-219

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q3 2029

Trials by Indication[1]

Seizure1 trial

Epilepsy1 trial

Focal Seizure1 trial

Bipolar 1 Disorder1 trial

References

Drug Info

Quick Facts

Related News